Keywords
How to Cite
Abstract
The authors analyze changes in serum levels of interleukin-1β (IL-1β) and determine its associative relationships with anthropometric parameters and metabolic profile in patients with type 2 diabetes depending on the presence of nonalcoholic fatty liver disease (NAFLD). Our results show that a maximum concentration of cytokine detected in NAFLD patients with elevated transaminases (47.09±17.86 pg/ml), which was significantly higher than for the other groups (p<0.001). In NAFLD patients with a normal range of liver enzymes compared to the control group, we found a tendency to increasing IL-1β (33.71±12.8 vs 26.84±10.85 pg/ml, p=0.078). In all groups obesity and insulin resistance were independent determinants associated with IL-1β in regression analysis. In patients with NAFLD compared to the control group we have further noted an association with HDL-C and TG levels, and in the group with elevated transaminases also with ALT.
References
2. Тронько М.Д., Лучицький Є.В., Паньків В.І. Ендокринні аспекти метаболічного синдрому // К.-Чернівці: Поліграфіст, 2005, 185. (Tronko M.D., Luchitsky Ye.V., Pan’kiv V.I. Endocrine aspects of metabolic syndrome. Kyiv – Chernivtsi: Poligrafist, 2005. 185 p.).
3. Боднар П.М., Михальчишин Г.П., Кобиляк Н.М. Неалкогольна жирова хвороба печінки у хворих на цукровий діабет типу 2: патогенез, діагностика та лікування (лекція) // Ендокринологія. 2012, 17, №1, 94-101. (Bodnar P.M., Mykhalchyshyn G.P., Kobyliak N.M. Nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: pathogenesis, diagnostics and treatment (lecture) // Endokrynologia. 2012, 17, N 1, 94-101).
4. Ludwig J., Viggiano T.R., McGill D.B. et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease // Mayo Clin Proc. 1980, 55, N 7, 434-438.
5. Angulo P. Nonalcoholic fatty liver disease // N. Engl. J. Med. 2002, 346, 1221-1231.
6. Day C.P. Pathogenesis of steatohepatitis // Best. Pract. Res. Clin. Gastroenterol. 2002, 16, N 5, 663-678.
7. Day C.P., James O.F. Steatohepatitis: a tale of two «hits»? // Gastroenterology. 1998, 114, N 4, 842-845.
8. Kamari Y., Shaish A., Vax E. et al. Lack of interleukin-1alpha or interleukin-1beta inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice // J Hepatol. 2011, 55, 1086-1094.
9. Tilg H., Moschen A.R. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis // Hepatology. 2010, 52, 1836-1846.
10. Chalasani N., Younossi Z., Lavine J.E. et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association // Hepatology. 2012, 55, N6, 2005-2023.
11. Wu W.C., Zhao W., Li S. Small intestinal bacteria overgrowth decreases small intestinal motility in the NASH rats // World J. Gastroenterol. 2008, 14, 313–317.
12. Imaeda A.B., Watanabe A., Sohail M.A. et al. Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome // J. Clin. Invest. 2009, 119, 305-314.
13. Miura K., Kodama Y., Inokuchi S. et al. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice // Gastroenterology. 2010, 139, 323-334.
14. Moschen A.R., Molnar C., Enrich B. et al. Adipose and liver expression of IL-1 family members in morbid obesity and effects of weight loss // Mol. Med. 2011, 17, N 7-8, 840-845.
15. Nov O., Kohl A., Lewis E.C. et al. Interleukin-1beta may mediate insulin resistance in liver-derived cells in response to adipocyte inflammation // Endocrinology.
2010, 151, 4247-4256.